Literature DB >> 11779903

Extending tissue plasminogen activator use to community and rural stroke patients.

José G Merino1, Brian Silver, Edward Wong, Blaine Foell, Bart Demaerschalk, Arturo Tamayo, Fali Poncha, Vladimir Hachinski.   

Abstract

BACKGROUND AND
PURPOSE: Guidelines for intravenous tissue plasminogen activator (tPA) use in stroke emphasize the importance of limiting its use to facilities with imaging capabilities and stroke expertise. This prospective case series set out to evaluate the safety of tPA use in patients referred from rural communities to a tertiary center.
METHODS: Prospective data of 82 consecutive patients treated with tPA in London, Ontario, were reviewed.
RESULTS: Twenty-three patients were transferred to London from a rural hospital (non-London patients); 49 were first evaluated in a London emergency room (London ER); and 10 were inpatients in a London hospital at the time of stroke onset. Mean transfer time and distance to London for non-London patients were 89 minutes and 41 miles. Although symptom onset to London ER times were longer for non-London than for London ER patients (123 versus 53 minutes), the door to needle times were significantly shorter for the former (49 versus 95 minutes, P<0.005). Imaging to needle times were longer for London inpatients compared with London ER patients (55 versus 36 minutes, P=0.16). The proportion of patients with >4-point improvement on the NIH Stroke Scale or cure at 24 hours was 57%, with no difference among groups (P=0.46). The overall symptomatic hemorrhage rate at 36 hours was 2%. No significant differences in outcomes were observed at 3 months.
CONCLUSIONS: This prospective study suggests that it is feasible and safe to treat rural patients referred to a tertiary care center with tPA, thus extending the benefits of thrombolysis for acute stroke to a wider population.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11779903     DOI: 10.1161/hs0102.100481

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  13 in total

Review 1.  Alteplase for stroke: money and optimistic claims buttress the "brain attack" campaign.

Authors:  Jeanne Lenzer
Journal:  BMJ       Date:  2002-03-23

Review 2.  Clinical trials of treatments for stroke.

Authors:  John Blass
Journal:  Curr Atheroscler Rep       Date:  2002-07       Impact factor: 5.113

3.  Emergency department arrival times after acute ischemic stroke during the 1990s.

Authors:  Dawn O Kleindorfer; Joseph P Broderick; Jane Khoury; Matthew L Flaherty; Daniel Woo; Kathleen Alwell; Charles J Moomaw; Arthur Pancioli; Edward Jauch; Rosie Miller; Brett M Kissela
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

4.  Can online benchmarking increase rates of thrombolysis? Data from the Austrian stroke unit registry.

Authors:  Julia Ferrari; Leonhard Seyfang; Wilfried Lang
Journal:  J Neurol       Date:  2013-06-08       Impact factor: 4.849

5.  Use of telemedicine and helicopter transport to improve stroke care in remote locations.

Authors:  Mihaela Saler; Jeffrey A Switzer; David C Hess
Journal:  Curr Treat Options Cardiovasc Med       Date:  2011-06

Review 6.  Brain tissue salvage in acute stroke.

Authors:  Perttu J Lindsberg
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

7.  Access to intra-arterial therapies for acute ischemic stroke: an analysis of the US population.

Authors:  Shuichi Suzuki; Jeffrey L Saver; Phillip Scott; Reza Jahan; Gary Duckwiler; Sidney Starkman; Yafang Su; Chelsea S Kidwell
Journal:  AJNR Am J Neuroradiol       Date:  2004 Nov-Dec       Impact factor: 3.825

Review 8.  The chain of care enabling tPA treatment in acute ischemic stroke: a comprehensive review of organisational models.

Authors:  Maarten M H Lahr; Gert-Jan Luijckx; Patrick C A J Vroomen; Durk-Jouke van der Zee; Erik Buskens
Journal:  J Neurol       Date:  2012-08-23       Impact factor: 4.849

Review 9.  Development of regional programs to speed treatment of stroke.

Authors:  Jeffrey A Switzer; David C Hess
Journal:  Curr Neurol Neurosci Rep       Date:  2008-01       Impact factor: 5.081

Review 10.  Antithrombotic and thrombolytic therapy for ischemic stroke.

Authors:  Curtis Benesch
Journal:  Curr Atheroscler Rep       Date:  2003-07       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.